Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by RPINVESTOR1on Dec 17, 2019 4:21pm
73 Views
Post# 30465498

RE:RE:RE:RE:RE:RE:Could shiseido be waiting for dermal injector?

RE:RE:RE:RE:RE:RE:Could shiseido be waiting for dermal injector?Hi Inv3strr:-

If Shiseido made an offer before March 1, 2020 (say 15 dollars), I would assume that the warrant holders would have the right to convert their warrants (2 dollars coversion price) to common shares. Although the conversion would add 5.4 million dollars to Replicel's bank account, it would cost Shiseido 13 dollars net times 2.7 million shares or 35.1 million extra to buy the Company before March 1, 2020.

I think this is a possibility because we are not that far away from March 1, 2020. There is nothing stopping Shiseido from entering into negotiations with Replicel now with the intention of pulling the trigger after the warrants expire.

As I have mentioned before, Shiseido's behaviour is far from the type you want in a partner. I would be very reluctant to negotiate a licencing agreement with Shiseido for RCH01 Rights for the remainder of the World. Shiseido only have the Rights for Asia and I haven't noticed too many bald Asian males (compared to non-Asians) in the Greater Toronto Area where I live. Also, most Asian males and females (in Asia) who do have hair loss issues are not in a position to afford the product. The big money for this product will be made from customers in the West.

After looking at the results from the Phase 2 Trial, Replicel should 'suggest' to Shiseido to make an offer for the entire Company in order to secure all Rights.

Wishful thinking???? 
Bullboard Posts